12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Fukuoka, Japan
- Pfizer Investigational Site
-
Ohita, Japan
- Pfizer Investigational Site
-
-
Chiba
-
Noda, Chiba, Japan
- Pfizer Investigational Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan
- Pfizer Investigational Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan
- Pfizer Investigational Site
-
-
Oita-ken
-
Beppu-shi, Oita-ken, Japan
- Pfizer Investigational Site
-
-
Osaka
-
Toyonaka, Osaka, Japan
- Pfizer Investigational Site
-
-
Saga
-
Tosu, Saga, Japan
- Pfizer Investigational Site
-
-
Shizuoka
-
Hamamatsu, Shizuoka, Japan
- Pfizer Investigational Site
-
-
Tokyo
-
Edogawa-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Minato-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Musashino, Tokyo, Japan
- Pfizer Investigational Site
-
Setagaya-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Shinagawa-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Toshima-ku, Tokyo, Japan
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cigarette smokers who are motivated to stop smoking and have smoked an average of at least 10 cigarettes per day
Exclusion Criteria:
- Subjects who have used a nicotine replacement product within 30 days of the study screening visit or intend to use it during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
4-week continuous quit rate (CQR) for Weeks 9-12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Continuous abstinence for Weeks 9-52 and Weeks 9-24
|
|
Long-term quit rate at Week 52
|
|
4-week CQR for Weeks 4-7
|
|
7-day point prevalence of asbtinence Weeks 12, Week 24, and Week 52
|
|
Continuous abstinence from TQD (Week 1) through Week 12
|
|
Weekly average number of cigarettes smoked per day for Weeks 1-12
|
|
Evaluation of withdrawal symptoms by the Minnesota Nicotine Withdrawal Scale
|
|
Evaluation of smoking satisfaction by the Smoking Effects Inventory
|
|
Evaluation of urge to smoke by the Brief Questionnaire of Smoking Urges
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Nakamura M, Oshima A, Ohkura M, Arteaga C, Suwa K. Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers. Clin Ther. 2014 Jun 1;36(6):918-27. doi: 10.1016/j.clinthera.2014.03.013. Epub 2014 May 5.
- Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007 Jun;29(6):1040-56. doi: 10.1016/j.clinthera.2007.06.012.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A3051046
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.